In the last trading session, 4.65 million shares of the Abbott Laboratories (NYSE:ABT) were traded, and its beta was 0.65. Most recently the company’s share price was $118.73, and it changed around -$0.06 or -0.05% from the last close, which brings the market valuation of the company to $209.44B. ABT currently trades at a discount to its 52-week high of $128.54, offering almost -8.26% off that amount. The share price’s 52-week low was $97.76, which indicates that the current value has risen by an impressive 17.66% since then. We note from Abbott Laboratories’s average daily trading volume that its 10-day average is 4.44 million shares, with the 3-month average coming to 6.36 million.
Abbott Laboratories stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.80. If we narrow it down even further, the data shows that 1 out of 23 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 3 recommended ABT as a Hold, whereas 15 deemed it a Buy, and 1 rated it as Underweight. Abbott Laboratories is expected to report earnings per share of $1.01 for the current quarter.
Abbott Laboratories (NYSE:ABT) trade information
Instantly ABT has showed a red trend with a performance of -0.05% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 120.00 on Tuesday, 07/20/21 increased the stock’s daily price by 1.06%. The company’s shares are currently up 8.44% year-to-date, but still up 0.07% over the last five days. On the other hand, Abbott Laboratories (NYSE:ABT) is 7.61% up in the 30-day period. We can see from the shorts that 14.01 million shares have been sold at a short interest cover period of 1.77 day(s).
The consensus price target as assigned by Wall Street analysts is $124.58, which translates to bulls needing to increase their stock price by 4.7% from its current value. Analyst projections state that ABT is forecast to be at a low of $109.00 and a high of $136.00. In order for the stock price to hit the forecast high, the stock would need to plunge -14.55% from its current level, while the stock would need to crash 8.2% from its current level to reach the projected low.
Abbott Laboratories (ABT) estimates and forecasts
Abbott Laboratories share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 5.47 percent over the past six months and at a 19.18% annual growth rate that is well above the industry average of 16.30%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain 77.20% in revenue this quarter, and will report a decrease of -1.00% in the next quarter. The year-over-year growth rate is expected to be 13.50%, up from the previous year.
Consensus estimates provided by 15 financial analysts predict the company will bring in an average of $9.67 billion in revenue for the current quarter. 15 analysts expect Abbott Laboratories to make $9.47 billion in revenue for the quarter ending Sep 2021. The company’s sales for the same quarters a year ago were $6.81 billion and $8.85 billion respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 42.10%. Forecasts for the next quarter put sales growth at 7.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 7.80%. Abbott Laboratories earnings are expected to increase by 24.50% in 2021, but the outlook is positive 12.84% per year for the next five years.
Abbott Laboratories’s next quarterly earnings report is expected to be released around October 19 and October 25. The annual dividend yield of the stock is 1.52 percent and its annual dividend per share was 1.80. It is important to note, however, that the 1.52% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision. The average dividend yield for the past five years averaged 1.74 per year.
Abbott Laboratories (NYSE:ABT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.72% of Abbott Laboratories shares, and 75.71% of them are in the hands of institutional investors. The stock currently has a share float of 76.26%. Abbott Laboratories stock is held by 3,119 institutions, with Vanguard Group, Inc. (The) being the largest institutional investor. By Mar 30, 2021, it held 8.25% of the shares, which is about 146.57 million shares worth $17.56 billion.
Blackrock Inc., with 7.55% or 134.07 million shares worth $16.07 billion as of Mar 30, 2021, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund were the top two Mutual Funds as of Mar 30, 2021. The former held 49.94 million shares worth $5.99 billion, making up 2.81% of all outstanding shares. On the other hand, Vanguard 500 Index Fund held roughly 36.28 million shares worth around $4.35 billion, which represents about 2.04% of the total shares outstanding.